Sana Biotechnology

Historical price data

Sana Biotechnology is at the forefront of developing a new class of engineered cell therapies designed to be broadly accessible. The company is advancing a pipeline of innovative candidates, including stem cell-derived pancreatic islets for type 1 diabetes and in vivo CAR T therapies for B-cell malignancies and autoimmune disorders. With a seasoned leadership team and a focus on overcoming key challenges in cell therapy like immune rejection and scalable manufacturing, Sana aims to deliver durable, one-time cures for a wide range of serious diseases.

Sana develops two core platforms: 1) An ex vivo 'Hypoimmune' platform to create universal cell therapies that evade immune rejection, and 2) An in vivo 'Fusogen' platform to genetically engineer a patient's cells directly inside the body.

4 drugs in pipeline

Total raised: $2.0B

Sana competes with Vertex and CRISPR in diabetes cell therapy, and with numerous biotechs (e.g., Intellia, Beam, Allogene) in gene editing and allogeneic cell therapy. Its key differentiation is the combined focus on solving immune rejection (hypoimmune) and enabling targeted in vivo delivery (fusogen) to create more accessible and durable cell medicines.